Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Graves' Disease I: Introduction01:28

Graves' Disease I: Introduction

Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overactivity of the thyroid gland. It results from autoantibodies called thyroid-stimulating immunoglobulins (TSIs), which bind to thyroid-stimulating hormone (TSH) receptors, leading to overstimulation of hormone production and a hypermetabolic state.EtiologyAlthough considered idiopathic, Graves’ disease has well-established contributing factors. There is a strong genetic component, with increased prevalence in...
Loss of Tumor Suppressor Gene Functions01:12

Loss of Tumor Suppressor Gene Functions

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Early mortality risk stratification after SARS-CoV-2 infection.

Medicina intensiva·2021
Same author

Anti-Ku-positive juvenile dermatomyositis.

Clinical and experimental dermatology·2021
Same author

Relapsing-remitting linear ecchymosis.

Clinical and experimental dermatology·2021
Same author

Early mortality risk stratification after SARS-CoV-2 infection.

Medicina intensiva·2020
Same author

Type I and type IV systemic contact dermatitis to balsam of Peru with a particular reaction to cinnamyl alcohol.

Clinical and experimental dermatology·2020
Same author

Neonatal erythroderma.

Clinical and experimental dermatology·2020
Same journal

Identification of RRM2 as a key regulator of malignant epithelial cells in gastric cancer through single‑cell transcriptomics.

Oncology reports·2026
Same journal

Impact of WFDC2 on the biological functions of cervical cancer cells and the regulation of the ERK/NF‑κB signaling pathway.

Oncology reports·2026
Same journal

Schisandrin B exhibits anti‑proliferative effects by inducing ferroptosis in pancreatic cancer.

Oncology reports·2026
Same journal

Research advances on DKK1 in head and neck squamous cell carcinoma: Linking molecular mechanisms to clinical applications (Review).

Oncology reports·2026
Same journal

PI3Kδ inhibitor YY‑20394 is effective alone or in combination with Bcl‑2 inhibitor ABT199 in acute myeloid leukemia cells.

Oncology reports·2026
Same journal

A fibroblast activation protein degrader enhances cisplatin sensitivity in non‑small cell lung cancer.

Oncology reports·2026
See all related articles

Related Experiment Video

Updated: Jun 1, 2026

Yeast As a Chassis for Developing Functional Assays to Study Human P53
14:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

P53 gene alterations in differentiated thyroid cancers.

M Herrmann1, D Baunoch, M Maliarik

  • 1SUNY STONY BROOK,DEPT SURG & PATHOL,STONY BROOK,NY 11794. UNIV CHICAGO,SCH MED,DEPT SURG & PATHOL,CHICAGO,IL 60637. HENRY FORD HOSP,DEPT SURG PULM RES & PATHOL,DETROIT,MI 48202. MICHIGAN CANC FDN,MOLEC CANC GENET LABS,DETROIT,MI 48201. ROCHESTER INST TECHNOL,ROCHESTER,NY 14623. UNIV MICHIGAN,SCH MED,DEPT SURG,ANN ARBOR,MI. WAYNE STATE UNIV,CTR MOLEC BIOL,DETROIT,MI. WAYNE STATE UNIV,DEPT ENDOCRINOL,DETROIT,MI. BAY STATE MED CTR,DEPT OBSTET GYNECOL RES,SPRINGFIELD,MA.

Oncology Reports
|May 21, 2011
PubMed
Summary
This summary is machine-generated.

TP53 gene alterations, including deletions and mutations, were identified in various human thyroid cancer subtypes. These alterations were found in differentiated papillary thyroid cancers, challenging previous assumptions about their occurrence only in undifferentiated stages.

More Related Videos

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence
04:56

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence

Published on: December 30, 2025

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

Related Experiment Videos

Last Updated: Jun 1, 2026

Yeast As a Chassis for Developing Functional Assays to Study Human P53
14:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence
04:56

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence

Published on: December 30, 2025

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Thyroid cancer encompasses several subtypes, including papillary (PTC), follicular (FTC), and medullary (MTC).
  • The role of p53 gene alterations in thyroid tumorigenesis is an area of ongoing investigation.
  • Previous studies suggested p53 alterations are primarily associated with advanced or undifferentiated thyroid cancer stages.

Purpose of the Study:

  • To investigate the frequency and types of p53 gene alterations in human thyroid cancers.
  • To determine the association of p53 alterations with different thyroid cancer subtypes and clinical stages.
  • To clarify the role of p53 alterations in differentiated versus undifferentiated thyroid cancer.

Main Methods:

  • Analysis of 22 human thyroid cancer samples (PTC, FTC, MTC).
  • Polymerase Chain Reaction - Single Strand Conformation Polymorphism (PCR-SSCP) for mutation detection.
  • Immunohistochemistry for p53 protein expression and mutation analysis.

Main Results:

  • Four deletions and three mutations in the p53 gene were detected across the analyzed thyroid cancer samples.
  • Deletions involved exons 1, 2-3, and 5-6 in papillary thyroid cancers.
  • Mutations were found in exons 2-3 (medullary thyroid cancers) and exons 8-9 (papillary thyroid cancer).
  • p53 alterations were observed in recurrent tumors and tumors that developed into cell lines.
  • Immunohistochemistry revealed p53 mutations in differentiated areas of papillary thyroid cancers, occurring from stage T1 to T4.

Conclusions:

  • p53 gene alterations are present in various human thyroid cancer subtypes, including differentiated papillary thyroid cancers.
  • The findings indicate that p53 mutations are frequent events in differentiated papillary thyroid cancers, contrary to previous literature.
  • These alterations occur across multiple clinical stages (T1-T4), suggesting an earlier role in thyroid cancer development than previously recognized.